Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL3408851 | 1.00 | FFAR3 (0.47) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL27743181 | 1.00 | FFAR3 (0.47) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL27596493 | 0.97 | FFAR3 (0.44) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL19356582 | 0.97 | FFAR3 (0.50) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL28664565 | 0.97 | FFAR3 (0.50) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL16244302 | 0.97 | FFAR3 (0.50) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL28549045 | 0.97 | FFAR3 (0.50) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL22152 | 0.97 | FFAR3 (0.50) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL31218573 | 0.97 | FFAR3 (0.50) | FFAR3LCKFYNCHRM2CHRM4 | |
| Acetic Acid SCHEMBL28289424 | 0.97 | FFAR3 (0.50) | FFAR3LCKFYNCHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109254097-B | Method for separating and analyzing Z3 and related impurities in intermediate Z3 of bulk drug of atorvastatin through high performance liquid chromatography | 重庆华邦胜凯制药有限公司 | 2021-11-30 | — | — | CN | claimed |
| CN-106918651-B | Method for detecting related substances of posaconazole | 江苏先声药业有限公司 | 2021-06-04 | — | — | CN | claimed |
| CN-109254097-A | The method of Z3 and relative substance in a kind of high performance liquid chromatography separation analysis Acrivastine bulk pharmaceutical chemicals intermediate Z3 | 重庆华邦胜凯制药有限公司 | 2019-01-22 | — | — | CN | claimed |
| CN-106918651-A | A kind of relevant substance detecting method of posaconazole | 江苏先声药业有限公司 | 2017-07-04 | — | — | CN | claimed |
| CN-113117657-B | Preparation and application of beta-cyclodextrin metal organic framework material HPLC column | 中南民族大学 | 2022-12-13 | — | — | CN | disclosed |
| US-11332779-B2 | Nucleic acid melting analysis with saturation dyes | BIOFIRE DEFENSE, LLC (US) | 2022-05-17 | — | — | US | disclosed |
| CN-114099437-A | Stable camptothecin pharmaceutical compositions | 易普森生物制药有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114073678-A | Stable camptothecin pharmaceutical compositions | 易普森生物制药有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-113767105-A | Heterocyclic compounds as inhibitors of monoacylglycerol lipases (MAGL) | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-109254097-B | Method for separating and analyzing Z3 and related impurities in intermediate Z3 of bulk drug of atorvastatin through high performance liquid chromatography | 重庆华邦胜凯制药有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-109254097-B | Method for separating and analyzing Z3 and related impurities in intermediate Z3 of bulk drug of atorvastatin through high performance liquid chromatography | 重庆华邦胜凯制药有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-108366965-B | Stable camptothecin pharmaceutical compositions | 易普森生物制药有限公司 | 2021-10-01 | — | — | CN | disclosed |
| WO-2004038038-A2 | AMPLICON MELTING ANALYSIS WITH SATURATION DYES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040034022-A1 | Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride | GODECKE GMBH (DE) | 2004-02-19 | — | — | US | disclosed |
| US-20020160396-A1 | Methods for labeling nucleotides, labeled nucleotides and useful intermediates | PRIMOSA INTERNATIONAL N.V. (AN) | 2002-10-31 | — | — | US | disclosed |
| EP-0937090-B1 | METHODS FOR LABELING NUCLEOTIDES, LABELED NUCLEOTIDES AND USEFUL INTERMEDIATES | KREATECH BIOTECH BV (NL) | 2002-08-07 | — | — | EP | disclosed |
| US-6338943-B1 | NUCLEOTIDE LABELS | KREATECH BIOTECHNOLOGY B.V. (NL) | 2002-01-15 | — | — | US | disclosed |
| EP-0937090-A1 | METHODS FOR LABELING NUCLEOTIDES, LABELED NUCLEOTIDES AND USEFUL INTERMEDIATES | Kreatech Biotechnology B.V. (NL) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998015564-A1 | METHODS FOR LABELING NUCLEOTIDES, LABELED NUCLEOTIDES AND USEFUL INTERMEDIATES | KREATECH BIOTECHNOLOGY B.V. (NL) | 1998-04-16 | — | — | WO | disclosed |
| CN-1159758-A | Peptides, methods for obtaining and derivatizing peptides and pharmaceutical compositions based on derivatised peptides | V I DEIGIN (RU) | 1997-09-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160396-A1 | Methods for labeling nucleotides, labeled nucleotides and useful intermediates | DUT, NUDT1, NT5E | AGTR1 3943/4885FFAR3 3716/4885LCK 3895/4885 |
| US-20040034022-A1 | Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride | TP53, ABL1, PRKDC | AGTR1 214/4885FFAR3 2283/4885LCK 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.